To succeed, pharmaceutical and life sciences companies need to maintain financially sustainable, fiscally healthy operations and adopt strategies to accelerate performance, maximize resources, and find new sources of revenue.
The downturn in the global economy has forced pharmaceutical and life sciences companies to focus on cost-saving initiatives, putting stress on finance departments. Although optimizing costs will always be important, reinvigorating R&D will most likely be a top strategic initiative for these companies as well. Most big pharmaceutical companies are under competitive pressure from generic drug makers — pressure that will become more intense as an increasing number of patents for “blockbuster” drugs expire during the next few years. Traditional companies may now find it strategically beneficial to place significant focus on leveraging their pipelines and entering new business ventures, such as licensing deals and acquisitions.
Our quarterly updates provide insights into deal activity in the pharma and life sciences industries.
CEOs are redirecting investments and strategies against a backdrop of global fiscal and economic uncertainties.